The future of interventional management of hypertension: Threats and opportunities

Current Vascular Pharmacology

Volumn 12, Issue 1, 2014, Pages 69-76

  Briasoulis, Alexandros ^a   Bakris, George ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Baroreflex activation therapy; Renal sympathetic denervation; Resistant hypertension

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN II; BETA 1 ADRENERGIC RECEPTOR; INSULIN; LEPTIN; NORADRENALIN; OXYTOCIN; RENIN; SPIRONOLACTONE; VASOPRESSIN;

ADRENAL BLOOD FLOW; ADRENERGIC SYSTEM; ARTERIAL PRESSURE; BLOOD PRESSURE REGULATION; CAROTID ARTERY BIFURCATION; CAROTID SINUS; CAROTID SINUS PRESSORECEPTOR; DISEASE COURSE; ELECTROSTIMULATION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE VARIABILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SLEEP DISORDERED BREATHING; SYMPATHETIC NERVE; SYMPATHETIC TONE;

BAROREFLEX; BLOOD PRESSURE; CAROTID SINUS; CATHETER ABLATION; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; KIDNEY; PRESSORECEPTORS; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84897446119     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990137     Document Type: Review

References (55)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303(20): 2043-50.
2. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in 5 European countries, Canada, and the United States. Hypertension 2004, 43: 10-17.
3. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117: e510-e526.
4. Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 2010; 90(2): 513-57.
5. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-504.
6. Abboud FM. Integration of reflex responses in the control of blood pressure and vascular resistance. Am J Cardiol 1979; 44: 903-911.
7. Grassi G, Seravalle G, Quarti-Trevano F, et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension 2009; 53: 205-209.
8. Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097-3101.
9. Sun C, Zubcevic J, Polson JW, et al. Shift to an involvement of phosphatidylinositol 3-kinase in angiotensin II actions on nucleus tractus solitarii neurons of the spontaneously hypertensive rat. Circ Res 2009; 105, 1248-1255.
10. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5: 86-99.
11. Grassi G, Cattaneo BM, Seravalle G, et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31: 68-72.
12. GrassiG, Seravalle G, Quarti-Trevano F, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension 2007; 49: 535-541.
13. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108, 560-565.
14. Ciriello J. Afferent renal inputs to paraventricular nucleus vasopressin and oxytocin neurosecretory neurons. Am J Physiol 1998; 275: R1745-R1754.
15. Coote JH. A role for the paraventricular nucleus of the hypothalamus in the autonomic control of heart and kidney. Exp Physiol 2004; 90: 169-173.
16. Echtenkamp ST, Dandridge PF. Sympathetic nerve stimulation on renal function in the primate. Am J Physiol 1989; 257: F204-F209.
17. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol 1983, 245: F1-F14.
18. Hausberg M, Kosch M, Harmelinck P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002, 106: 1974-1979.
19. Holmer S, Rinne B, Eckardt KU, et al. Role of renal nerves for the expression of renin in adult rat kidney. Am J Physiol 1994; 266: F 738-F 745.
20. Katholi RE, Hageman GR, Whitlow PL, et al. Hemodynamic and afferent renal nerve responses to intrarenal adenosine in the dog. Hypertension 1983, 5(Supp 1): I-149-I-154.
21. Katholi RE, Whitlow PL, Hageman GR, et al. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertension 1984, 2: 349-359.
22. Lohmeier TE, Hildebrandt DA, Warren S, et al. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am J Physiol Regul Integr Comp Physiol 2005; 288: R828-R836.
23. McCubbin J, Green J, Page I. Baroreceptor function in chronic renal hypertension. Clin Res 4: 205-210, 1956.
24. Chapleau MW, Hajduczok G, Abboud FM. Mechanisms of resetting of arterial baroreceptors: an overview. Am J Med Sci 295: 327-334, 1988.
25. Bristow JD, Honour AJ, Pickering GW, et al. Diminished baroreflex sensitivity in high blood pressure. Circulation 1969, 39: 48-54.
26. Lohmeier TE, Irwin ED, Rossing MA, et al. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004; 43: 306-311.
27. Lohmeier TE, Dwyer TM, Irwin ED, et al. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension 2007; 49: 1307-1314.
28. Lohmeier TE, Iliescu R, Dwyer TM, et al. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol 2010; 299: H402-H409.
29. Lohmeier TE, Hildebrandt DA, Dwyer TM, et al. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension 2007; 49: 373-379.
30. Lohmeier TE, Dwyer TM, Hildebrandt DA, et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension 2005; 46: 1194-1200.
31. Lohmeier TE, Hildebrandt DA, Dwyer TM, et al. Prolonged activation of the baroreflex decreases arterial pressure even during chronic adrenergic blockade. Hypertension 2009; 53: 833-838.
32. Bilgutay A, Lillehei W. Surgical treatment of hypertension with reference to baropacing. Am J Cardiol 1966, 17: 663-667.
33. Griffith L, Schwartz S. Reversal of renal hypertension by electrical stimulation of the carotid sinus nerve. Surgery 1964; 56: 232-236.
34. Tuckman J, Reichman T, Lyon A, et al. Electrical stimulation of the sinus nerves in hypertensive patients: clinical evaluation and physiological studies. Hypertension 1967, 194S: 23-28.
35. Scheffers I, Kroon AA, Tordoir J, et al. Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension. Expert Rev Med Devices 2008; 5: 33-39.
36. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006; 44: 123-1218.
37. Tordoir JH, Scheffers I, Schmidli J, et al. An implantable carotid sinus baroreflex activating system: surgical technique and shortterm outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg 2007; 33: 414-421.
38. Bisognano J, Sloand J, Papademetriou V, et al. An implantable carotid sinus baroreflex activating system for drug-resistant hypertension: interim chronic efficacy results from the multicenter Rheos Feasibility Trial. Circulation 2006, 114(18 Suppl): II575.
39. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multicenter feasibility study. J Am Coll Cardiol 2010; 56: 1254-1258.
40. Wustmann K, Kucera JP, Scheffers I, et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009; 54: 530-536.
41. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol 2011; 58: 765-73.
42. Ferguson G, Eliasziw M, Barr H, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. Stroke 1999; 30: 1751-8.
43. Sajid M, Vijaynagar B, Singh P, Hamilton G. Literature review of cranial nerve injuries during carotid endarterectomy. Acta Chir Belg 2007; 107: 25-8.
44. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6: 152-8.
45. Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P; DEBuT-HT and Rheos Feasibility Trial Investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 2011; 57: 1787-8.
46. Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012; 6: 270-6.
47. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1953; 1: 403-408.
48. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
49. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet 2010; 376: 1903-1909.
50. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens 2012; 30: 874-6.
51. Symplicity HTN-3 Investigators. Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3). ClinicalTrials. gov NCT01418261.
52. Petidis K, Anyfanti P, Doumas M. Renal sympathetic denervation: renal function concerns. Hypertension 2011; 58: e19.
53. Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 2011; 58(11): 1176-82.
54. Brandt MC, Mahfoud F, Reda S. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59(10): 901-9.
55. Witkowski A, Prejbisz A, Florczak E. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-65.